Cargando…

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review

BACKGROUND: Herein, we report a complete response after whole brain radiotherapy (WBRT) and concomitant T-DM1 in a patient with HER2-positive metastatic breast cancer (MBC) and extensive brain and leptomeningeal involvement. CASE PRESENTATION: A 46 years old Caucasian woman with HER2-positive MBC an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricciardi, Giuseppina Rosaria Rita, Russo, Alessandro, Franchina, Tindara, Schifano, Silvia, Mastroeni, Giampiero, Santacaterina, Anna, Adamo, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784540/ https://www.ncbi.nlm.nih.gov/pubmed/29370839 http://dx.doi.org/10.1186/s12885-018-3994-5

Ejemplares similares

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2016)

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer
por: Russo, Alessandro, et al.
Publicado: (2017)

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
por: Russo, Alessandro, et al.
Publicado: (2019)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study
por: Pergolizzi, Stefano, et al.
Publicado: (2011)

Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
por: Russo, Alessandro, et al.
Publicado: (2018)

The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
por: Adamo, Barbara, et al.
Publicado: (2017)

Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
por: Adamo, Barbara, et al.
Publicado: (2019)

Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis
por: Puliafito, Ivana, et al.
Publicado: (2023)

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
por: Franchina, Mariausilia, et al.
Publicado: (2023)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
por: Adamo, Vincenzo, et al.
Publicado: (2019)

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
por: Lu, Nu T., et al.
Publicado: (2015)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Ovarian Adenocarcinoma With Leptomeningeal Metastases
por: Bayas, Angel, et al.
Publicado: (2022)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
por: Lazaratos, Anna-Maria, et al.
Publicado: (2023)

P39.09 Social Media Support of Lung Cancer Patient Associations During the Lockdown Restrictions in Italy: A Breath of Life During the COVID-19 Pandemic.
por: Franchina, V., et al.
Publicado: (2021)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni, Antonio, et al.
Publicado: (2016)

Helical tomotherapy in patients with leptomeningeal metastases
por: Schiopu, Sanziana RI, et al.
Publicado: (2018)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020)

Metastatic Melanoma With Leptomeningeal Disease
por: Marinova, Amanda M., et al.
Publicado: (2021)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database
por: Russo, Giulia, et al.
Publicado: (2023)

Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2021)

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors
por: Le Rhun, Emilie, et al.
Publicado: (2013)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Anorectal Cancer with Bone Marrow and Leptomeningeal Metastases
por: Zeeneldin, Ahmed, et al.
Publicado: (2018)

How we treat patients with leptomeningeal metastases
por: Le Rhun, Emilie, et al.
Publicado: (2019)

Dural and Leptomeningeal Spine Metastases of Breast Cancer
por: Matos, Fernando, et al.
Publicado: (2019)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Leptomeningeal Metastases: New Opportunities in the Modern Era
por: Wilcox, Jessica A., et al.
Publicado: (2022)

Editorial: Brain and leptomeningeal metastases in lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2023)

Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases
por: Khaled, Mariam Lotfy, et al.
Publicado: (2023)

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
por: Malani, Rachna, et al.
Publicado: (2020)

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
por: Niikura, Naoki, et al.
Publicado: (2023)

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status
por: Bronte, Giuseppe, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vibn5v1hb986ft1c5b9lgaqtd0